Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children
Key facts
- Phase
- Phase 1/2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 18 years old?
Source: NCT07193719, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Charite University, Berlin, Germany
- Trial code
- NCT07193719
- Record updated
- 15 October 2026
- Original description
The goal of this randomized interventional clinical trial is to learn if a standardized lung volume optimization maneuver (LVOM) is beneficial inRead full original descriptionShow less
Influence of a Personalized Lung Volume Optimization Maneuver on Lung Aeration and Cardiac Performance in Mechanically Ventilated Children
The goal of this randomized interventional clinical trial is to learn if a standardized lung volume optimization maneuver (LVOM) is beneficial in
1. study) children undergoing biventricular repair of their congenital heart disease (CHD) with cardiopulmonary bypass and 2. study) in children with severe respiratory failure at risk for or need for ECMO.
The main questions it aims to answer are:
Main hypotheses of CHD study: Does a standardized PEEP-Titration maneuver, to optimize end-expiratory lung volume improve:
* cardiac performance * lung function
Does it make a difference in:
* length of ventilation * ventilation/perfusion mismatch of the lung * need for vasopressor support?
Main hypotheses of ECMO study:
Does a LVOM in children/infants with severe respiratory failure /ARDS
* improve lung compliance and gas exchange * facilitate lung protective ventilation according to PALICC-2 guidelines * improve lung aeration and V/Q-matching assessed with EIT
Does it make a difference in
* need for ECMO * duration of ECMO runs * hemodynamics stability
Inclusion: congenital heart disease; surgery with cardiopulmonary bypass.
Exclusion: chronic lung disease; patients with respiratory failure on ECMO or at risk for ECMO; severe lung hypoplasia or interstitial lung disease; <36weeks of gestational age; single ventricle physiology; ECMO/VAD; Endotracheal tube leak > 15%; lack of informed consent from parents; ECMO study Inclusion Criteria; invasive ventilation.
CHD study:.